Elevation Oncology, Inc. (ELEV)
After hours:
| Previous Close | 3.6450 |
| Open | 3.6800 |
| Bid | 3.5700 x 100 |
| Ask | 3.6300 x 500 |
| Day's Range | 3.5799 - 3.8300 |
| 52 Week Range | 0.3630 - 5.8900 |
| Volume | |
| Avg. Volume | 1,171,028 |
| Market Cap | 176.117M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.75 |
PR NewswireElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
- GuruFocus.com
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023
Strategic Advances Amidst Financial Prudence
- PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements.
